Edurant (Rilpivirine) – HIV-1 Treatment Medication | NNRTI Antiretroviral Therapy

Edurant® (rilpivirine) is a prescription antiretroviral medication used in combination with other drugs for the treatment of HIV-1 infection in adults. It belongs to the class of non-nucleoside reverse transcriptase inhibitors (NNRTIs) and works by blocking the reverse transcriptase enzyme, helping prevent the virus from multiplying in the body.

When used as part of a complete combination antiretroviral therapy (ART) regimen, Edurant helps reduce viral load, improve immune system function, and support long-term management of HIV infection.

Key Features & Benefits

• Effective NNRTI-based HIV-1 treatment

• Used in combination antiretroviral therapy (ART)

• Helps reduce HIV viral load

• Supports immune system health

• Once-daily oral tablet (taken with food)

• Suitable for long-term HIV management under medical supervision

How Edurant Works

Edurant (rilpivirine) blocks the action of reverse transcriptase, an enzyme HIV needs to replicate. By inhibiting viral replication, it helps slow disease progression and supports sustained viral suppression when combined with other antiretroviral medicines.

Important Information

Edurant is not a cure for HIV and must always be used in combination with other antiretroviral medications as prescribed by a healthcare provider. Consistent daily use is essential for maintaining viral suppression and reducing the risk of resistance.

Common Side Effects

Side effects may include headache, insomnia, dizziness, nausea, or skin rash. Patients should be monitored regularly by a healthcare professional during treatment.